Boston Scientific Corporation (NYSE:BSX) exchanged hands 24,092,500 shares versus average trading capacity of 8.81M shares, while its relative trading volume is 2.84. Boston Scientific Corporation (NYSE:BSX)’s total market worth is $34.21B along with 1.36B outstanding shares.

Insiders has most recently took part in a trading activity, Pierce David A, SVP and President, Endoscopy of the company in a transaction that occurred 1/9/2017 sold 10,232 shares of the stock. The stock was sold at a price of $22.24, for a total value of $227,546. Subsequent to the transaction Pierce David A owned a total of 25,600 shares of the stock.

In a separate transaction on 1/9/2017, Pratt Timothy A., EVP, GC & Chief Admin Officer sold 6,195 shares of the stock. The stock was sold at a price of $22.24, for a total worth of $137,769. Succeeding to the transaction Pratt Timothy A. owned overall 231,273 shares of the stock.

Moreover, Fitzgerald Joseph Michael, EVP & President, CRM sold 8,454 shares of the stock in a reserved transaction that ensued on 1/1/2017. At a price of $21.63, the stock was sold for an entire value of $182,860. Consequent to the transaction Fitzgerald Joseph Michael owned a total of 99,612 shares of the stock.

Currently, 0.20% shares of Boston Scientific Corporation (NYSE:BSX) are owned by insiders with -10.04% six-month change in the insider ownership. The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. For Boston Scientific Corporation (NYSE:BSX) total 23 number of trades held during last 3 months and 160 during last 12 months, out of them 0 numbers of buys held in last 3 months and 24 buys in last 12 months. Whereas 23 numbers of sells held in last 3 months and 136 sells over the past 12 months.

For the duration of last three months Boston Scientific Corporation (NYSE:BSX)’s total number of shares bought are 0 and sold 369,753 from a total of 369,753 traded shares. During last twelve months 1,194,874 number of shares bought and 2,589,132 sold from a total of 3,784,006 shares traded. A net activity of 369,753 took place in the course of three months, while 1,394,258 during last twelve months. Insider trading information is derived from Forms 3 and 4 filings are filed with the U.S. Securities and Exchange Commission (SEC).

Boston Scientific Corporation (NYSE:BSX) ended last trading session at the price of $23.61 whereas a number of traders indicating mean target price will hit $27.55 over the next twelve months, mean value of price target most recently revised on 01/10/17. Boston Scientific Corporation (NYSE:BSX)’s highest estimates of price target are $31.00 and low forecast is $24.00 based on the opinion of 22 analysts. The price target estimates represents a standard deviation of 2.53. However brokerage recommendations suggests an ABR of 1.57 based on calls of 22 experts.

Boston Scientific Corporation (NYSE:BSX) is expected to release the earnings of its current quarter on 2/2/17 Before Market Open. The company is expected to release $0.29 EPS during current quarter according to 25 analysts whereas the company reported $0.26 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $0.28 and high estimate of $0.3. Boston Scientific Corporation (NYSE:BSX)’s average revenue estimates for the current quarter are $0.3 according to 22 number of analysts. However its lowest revenue estimates are $2.14B and highest revenue estimates are $2.19B. A year ago the company’s sales were $1.98B. Its yearly sales growth estimates are 9.30%. Past 5 years growth of Boston Scientific Corporation (NYSE:BSX) observed at 30.57%, and for the next five years the analysts that follow this company are expecting its growth at 12.44%.